Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Maryam Sadat Hosseini, Mojdeh Mohseni, Masood Naseripour, Mehdi Mirzaei, Kowsar Bagherzadeh, Sayyed Amirpooya Alemezadeh & Bita Mehravi. (2023) Synthesis and evaluation of modified lens using plasma treatment containing timolol-maleate loaded lauric acid-decorated chitosan-alginate nanoparticles for glaucoma. Journal of Biomaterials Science, Polymer Edition 34:13, pages 1793-1812.
Read now
Read now
Anna Bollinger, Chiara Jeiziner, Henriette E Meyer zu Schwabedissen, Kurt E Hersberger, Samuel S Allemann & Céline K Stäuble. (2023) Severe systemic Adverse Reactions to Ophthalmic Timolol in a CYP2D6 Homozygous *4 Allele Carrier: A Case Report. Pharmacogenomics 24:14, pages 739-746.
Read now
Read now
Ewa Mrukwa-Kominek, Marta Misiuk-Hojlo, Adrienne Csutak, Ingeborg Stalmans & Gerhard Garhofer. (2023) A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension. Current Medical Research and Opinion 39:5, pages 775-783.
Read now
Read now
Mohammad Pakravan, Afsaneh Naderi Beni, Shahin Yazdani, Hamed Esfandiari & Shahram Mirshojaee. (2021) Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma. Journal of Drug Assessment 10:1, pages 91-96.
Read now
Read now
Abhishek K. Sah & Preeti K. Suresh. (2017) Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate. Artificial Cells, Nanomedicine, and Biotechnology 45:3, pages 448-459.
Read now
Read now
Jukka Mäenpää & Olavi Pelkonen. (2016) Cardiac safety of ophthalmic timolol. Expert Opinion on Drug Safety 15:11, pages 1549-1561.
Read now
Read now
Claude Pinnock, Jennifer L. Y. Yip, Anthony P. Khawaja, Robert Luben, Shabina Hayat, David C. Broadway, Paul J. Foster, Kay-Tee Khaw & Nick Wareham. (2016) Topical Beta-Blockers and Cardiovascular Mortality: Systematic Review and Meta-Analysis with Data from the EPIC-Norfolk Cohort Study. Ophthalmic Epidemiology 23:5, pages 277-284.
Read now
Read now
Alvin Eisner & Shiuh-Wen Luoh. (2011) Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease. Current Eye Research 36:10, pages 867-885.
Read now
Read now
Philippe Denis. (2011) Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review. Expert Opinion on Pharmacotherapy 12:3, pages 463-471.
Read now
Read now
M Reza Razeghinejad & Mohammad Hosein Nowroozzadeh. (2010) Anti‐glaucoma medication exposure in pregnancy: an observational study and literature review. Clinical and Experimental Optometry 93:6, pages 458-465.
Read now
Read now
Duska J Sidjanin, Catherine A McCarty, Richard Patchett, Edward Smith & Russell A Wilke. (2008) Pharmacogenetics of Ophthalmic Topical β-Blockers. Personalized Medicine 5:4, pages 377-385.
Read now
Read now
Articles from other publishers (66)
David Cornwell, Zachary Goldstein, Bopha Chrea & Robert McLafferty. (2024) Timolol in the treatment of hard-to-heal wounds: a comprehensive review. Journal of Wound Care 33:4, pages 243-252.
Crossref
Crossref
Raageen Kanjee, Marko M. Popovic, Ali Salimi, Cindy M. L. Hutnik, Iqbal Ike K. Ahmed & Hady Saheb. (2024) Prophylaxis against intraocular pressure spikes following uncomplicated phacoemulsification: a systematic-review and meta-analysis. Eye.
Crossref
Crossref
I. A. Bulakh, A. V. Kuroyedov, A. V. Seleznev & Z. M. Nagornova. (2023) Specific features of impaired tolerance to antihypertensive treatment in patients with primary open-angle glaucoma and a hereditary history of the disease. National Journal glaucoma 22:3, pages 98-108.
Crossref
Crossref
Shiyao Gu, Qingyong Luo, Cen Wen, Yu Zhang, Li Liu, Liu Liu, Su Liu, Chunhua Chen, Qian Lei & Si Zeng. (2023) Application of Advanced Technologies—Nanotechnology, Genomics Technology, and 3D Printing Technology—In Precision Anesthesia: A Comprehensive Narrative Review. Pharmaceutics 15:9, pages 2289.
Crossref
Crossref
Larisa K. Moshetova, Maria M. Soshina, Ksenia I. Turkina, Elena A. Grishina, Zhannet A. Sozaeva, Anastasia A. Kachanova, Kristina A. Akmalova, Dmitriy V. Ivashchenko, Mikhail S. Zastrozhin, Vladimir P. Fisenko & Dmitry A. Sychev. (2023)
Effect of
CYP2D6*4
,
CYP2D6*10
polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma
. Drug Metabolism and Personalized Therapy 38:2, pages 143-148.
Crossref
Crossref
Samar A. Salim, Noha M. Badawi, Shahira H. EL-Moslamy, Elbadawy A. Kamoun & Baher A. Daihom. (2023) Novel long-acting brimonidine tartrate loaded-PCL/PVP nanofibers for versatile biomedical applications: fabrication, characterization and antimicrobial evaluation. RSC Advances 13:22, pages 14943-14957.
Crossref
Crossref
Shibal Bhartiya, Namrata Sharma, Saurabh Verma, Tanuj Dada, Meghal Gagrani, Nidhi Chauhan & Kanchan Satpute. (2023) Ocular and Systemic Factors Associated with Glaucoma. Journal of Current Glaucoma Practice 16:3, pages 179-191.
Crossref
Crossref
Yi‐An Lin, Wei‐Yu Chiang, William Chih‐Wei Chang, Ming‐Tse Kuo, Alexander Chen & Mei‐Chich Hsu. (2022) Urinary excretion patterns and potential risks of beta‐blocker ophthalmic drops in sports. Drug Testing and Analysis 15:1, pages 75-83.
Crossref
Crossref
Piotr Gadziński, Anna Froelich, Monika Wojtyłko, Antoni Białek, Julia Krysztofiak & Tomasz Osmałek. (2022) Microneedle-based ocular drug delivery systems – recent advances and challenges. Beilstein Journal of Nanotechnology 13, pages 1167-1184.
Crossref
Crossref
Hsin‐ya Yang, Fernando Fierro, Daniel J. Yoon, Anthony Gallegos, Stephanie L. Osborn, Alan V. Nguyen, Thomas R. Peavy, William Ferrier, Linda Talken, Betty W. Ma, Kristopher G. Galang, Andrea Medina Lopez, Daniel R. Fregoso, Heather Stewart, Eric A. Kurzrock, Athena M. Soulika, Jan A. Nolta & R. Rivkah Isseroff. (2022) Combination product of dermal matrix, preconditioned human mesenchymal stem cells and timolol promotes wound healing in the porcine wound model. Journal of Biomedical Materials Research Part B: Applied Biomaterials 110:7, pages 1615-1623.
Crossref
Crossref
Gedaliah May, Daniel Miller & Daniel Fuchs. (2022) Bradycardia From a Non-selective Beta-Adrenergic Antagonist, Timolol, Applied Ophthalmologically for Glaucoma. Cureus.
Crossref
Crossref
Antonio Greco, Marco Giuseppe Leto, Andrea Greco, Riccardo Merli & Agostino Salvatore Vaiano. 2022. Vision Correction and Eye Surgery. Vision Correction and Eye Surgery.
Michael Rode, Kolja Nenoff, Kerstin Wirkner, Katrin Horn, Andrej Teren, Ralf Regenthal, Markus Loeffler, Joachim Thiery, Achim Aigner, Janne Pott, Holger Kirsten & Markus Scholz. (2022) Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers. PLOS ONE 17:4, pages e0266897.
Crossref
Crossref
Oluwaseun O. Awe, Oluwadare Ogundare & Bernice O. Adegbehingbe. (2021) Assessment of parasympathetic cardiovascular activity in primary open-angle glaucoma. International Ophthalmology 42:4, pages 1111-1119.
Crossref
Crossref
Sawan R. Dalal, Vignesh Ramachandran, Radina Khalid, F. Keith Manuel, Julianne R. Knowles & Jeffrey A. Jones. (2021) Increased Intraocular Pressure in Glaucomatous, Ocular Hypertensive, and Normotensive Space Shuttle Crew. Aerospace Medicine and Human Performance 92:9, pages 728-733.
Crossref
Crossref
Yuta Saito, Junichiro Kizaki, Yoshihiro Wada, Yoshiyuki Shibasaki, Nobuharu Kishimoto & Makoto Aihara. (2021) Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. Japanese Journal of Ophthalmology 65:5, pages 598-607.
Crossref
Crossref
Mizuki Kita, Kazutaka Kanai, Hiroki Mitsuhashi, Tomoki Noguchi, Noriaki Nagai, Mizuki Yamaguchi, Yuya Otaka, Rina Kudo, Yohei Yamashita & Kazuki Tajima. (2021) Magnesium Hydroxide Nanoparticles Improve the Ocular Hypotensive Effect of Twice Daily Topical Timolol Maleate in Healthy Dogs. Veterinary Sciences 8:8, pages 168.
Crossref
Crossref
John Rains & Jacob Kesterson. (2021) Ocular timolol as the causative agent for symptomatic bradycardia in an 89-year-old female. The American Journal of Emergency Medicine 42, pages 263.e5-263.e6.
Crossref
Crossref
Daniel J. Yoon, Ramanjot Kaur, Anthony Gallegos, Kaitlyn West, Hsinya Yang, Saul Schaefer, Catherine Tchanque-Fossuo, Sara E. Dahle & R. Rivkah Isseroff. (2020) Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events. American Journal of Clinical Dermatology 22:1, pages 89-99.
Crossref
Crossref
L. K. Moshetova, M. M. Soshina & K. I. Turkina. (2020) Practical pharmacogenetics for personalized management of glaucoma patients. Pharmacogenetics and Pharmacogenomics:1, pages 26-34.
Crossref
Crossref
Andrew M. Peterson, Jake J. Lee, Dorina Kallogjeri, John S. Schneider, Murali M. Chakinala & Jay F. Piccirillo. (2020) Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia–Associated Epistaxis. JAMA Otolaryngology–Head & Neck Surgery 146:11, pages 1006.
Crossref
Crossref
Juan Francisco Mir‐Bonafé, Eduardo Rozas‐Muñoz, Eduard Pedemonte‐Sarrias, Marc Mir‐Bonafé, Jose María Mir‐Bonafé, Jaime Piquero‐Casals & Luis Puig. (2019) Psoriasis precipitated by timolol eye drops. A series of eight cases. Australasian Journal of Dermatology 61:1.
Crossref
Crossref
Sophie Dupuis-Girod, Vincent Pitiot, Cyrille Bergerot, Anne-Emmanuelle Fargeton, Marjolaine Beaudoin, Evelyne Decullier, Valentine Bréant, Bettina Colombet, Pierre Philouze, Frédéric Faure & Jean-Charles Letievant. (2019) Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Scientific Reports 9:1.
Crossref
Crossref
Letizia Negri, Antonio Ferreras & Michele Iester. (2019) Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. Journal of Ophthalmology 2019, pages 1-12.
Crossref
Crossref
Emanuela Falcinelli, Alessia Iannone, Anna Maria Mezzasoma, Lavinia Amato, Tiziana Fierro, Giuseppe Guglielmini, Carlo Cagini & Paolo Gresele. (2019) Inhibition of platelet function after ocular administration of non-steroidal anti-inflammatory drugs. Thrombosis Research 175, pages 1-5.
Crossref
Crossref
L. K. Moshetova, M. M. Soshina, D. A. Sychev & K. I. Turkina. (2019) Pharmacogenetics of timolol. Vestnik oftal'mologii 135:3, pages 137.
Crossref
Crossref
Anthony Gallegos, Thomas Peavy, Roy Dixon & Roslyn Rivkah Isseroff. (2018) Development of a novel ion-pairing UPLC method with cation-exchange solid-phase extraction for determination of free timolol in human plasma. Journal of Chromatography B 1096, pages 228-235.
Crossref
Crossref
Michael G. LancinaIIIIII, Juan Wang, Geoffrey S. Williamson & Hu Yang. (2018) DenTimol as A Dendrimeric Timolol Analogue for Glaucoma Therapy: Synthesis and Preliminary Efficacy and Safety Assessment. Molecular Pharmaceutics 15:7, pages 2883-2889.
Crossref
Crossref
Michael Levine & Jeffrey Brent. 2018. Critical Care Toxicology. Critical Care Toxicology
1
16
.
Alicia Fernández-Colino, Daniela A. Quinteros, Daniel A. Allemandi, Alessandra Girotti, Santiago D. Palma & F. Javier Arias. (2017) Self-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucoma. Molecular Pharmaceutics 14:12, pages 4498-4508.
Crossref
Crossref
Tavish Nanda, Nailyn Rasool, Alison B. Callahan, Robert L. Stamper & Jeffrey G. Odel. (2017) Ophthalmic Timolol Hallucinations: A Case Series and Review of the Literature. Journal of Glaucoma 26:9, pages e214-e216.
Crossref
Crossref
emre ertan şahin. (2017) Günlük pratikte kullanılan topikal oftalmik timolol’e bağlı gelişen ciddi bradikardi: Vaka örneği. Mersin Üniversitesi Sağlık Bilimleri Dergisi, pages 156-157.
Crossref
Crossref
Michael Levine & Jeffrey Brent. 2017. Critical Care Toxicology. Critical Care Toxicology
771
786
.
Katherine PüttgenAnne LuckyDenise AdamsElena PopeCatherine McCuaigJulie PowellDana FeigenbaumYulia SavvaEulalia BaselgaKristen HollandBeth DroletDawn SiegelKimberly D. MorelMaria C. GarzonErin MathesChristine LaurenAmy Nopper, Kimberly Horii, Brandon Newell, Wei Song & Ilona Frieden. (2016) Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics 138:3.
Crossref
Crossref
Shu-Fen Wung. (2016) Bradyarrhythmias. Critical Care Nursing Clinics of North America 28:3, pages 297-308.
Crossref
Crossref
Napoleone Ferrara & Anthony P. Adamis. (2016) Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery 15:6, pages 385-403.
Crossref
Crossref
C.T. Gunther‐Harrington, E.S. Ontiveros, T.E. Hodge, L.C. Visser & J.A. Stern. (2016) Effects of 0.5% Timolol Maleate Ophthalmic Solution on Heart Rate and Selected Echocardiographic Indices in Apparently Healthy Cats. Journal of Veterinary Internal Medicine 30:3, pages 733-740.
Crossref
Crossref
Lisa Weibel, Marjam J. Barysch, Helene S. Scheer, Ingo Königs, Kathrin Neuhaus, Clemens Schiestl, Katharina Rentsch, Daniel M. Müller & Martin Theiler. (2016) Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption. Pediatric Dermatology 33:2, pages 184-190.
Crossref
Crossref
Muhammad Asim Rana, Ahmed Fouad Mady, Basheer Abdel Rehman, Abdulrahman Alharthy, Basim Huwait, Asim Riaz & Waleed Tharwat Aletreby. (2015) From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient. Case Reports in Critical Care 2015, pages 1-4.
Crossref
Crossref
Nicole L. Pratt, Emmae N. Ramsay, Lisa M. Kalisch Ellett, Tuan A. Nguyen & Elizabeth E. Roughead. (2015) Association between Ophthalmic Timolol and Hospitalisation for Bradycardia. Journal of Ophthalmology 2015, pages 1-6.
Crossref
Crossref
Michael Levine & Jeffrey Brent. 2016. Critical Care Toxicology. Critical Care Toxicology
1
16
.
Annelies C. Ham, Karin M. A. Swart, Anke W. Enneman, Suzanne C. van Dijk, Sadaf Oliai Araghi, Janneke P. van Wijngaarden, Nikita L. van der Zwaluw, Elske M. Brouwer-Brolsma, Rosalie A. M. Dhonukshe-Rutten, Natasja M. van Schoor, Tischa J. M. van der Cammen, Paul Lips, Lisette C. P. G. M. de Groot, André G. Uitterlinden, Renger F. Witkamp, Bruno H. Stricker & Nathalie van der Velde. (2014) Medication-Related Fall Incidents in an Older, Ambulant Population: The B-PROOF Study. Drugs & Aging 31:12, pages 917-927.
Crossref
Crossref
Gerald Liewa & Jie Jin Wangba. (2014) Manifestaciones Vasculares Retinianas: ¿Reflejan el Estado del Corazón?. Highlights of Vitreoretina 7:1, pages 8-12.
Crossref
Crossref
Javier Moreno-Montañés, Belén Sádaba, Verónica Ruz, Almudena Gómez-Guiu, Javier Zarranz, María Victoria González, Covadonga Pañeda & Ana Isabel Jimenez. (2014) Phase I Clinical Trial of SYL040012, a Small Interfering RNA Targeting β-Adrenergic Receptor 2, for Lowering Intraocular Pressure. Molecular Therapy 22:1, pages 226-232.
Crossref
Crossref
Tamara Martínez, Maria Victoria González, Ingo Roehl, Natalia Wright, Covadonga Pañeda & Ana Isabel Jiménez. (2014) In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma. Molecular Therapy 22:1, pages 81-91.
Crossref
Crossref
Paul N. Schacknow & John R. Samples. 2014. Clinical Glaucoma Care. Clinical Glaucoma Care
417
477
.
Jennifer Sorrell & Sarah L. Chamlin. (2013) Topical Timolol 0.5% Gel‐Forming Solution for Small Deep Facial Infantile Hemangiomas. Pediatric Dermatology 30:5, pages 592-594.
Crossref
Crossref
U. Canpolat, K.M. Gürses, K. Aytemir & A. Oto. (2013) Severe bradycardia and syncope due to topical ophthalmic timololSchwere Bradykardie und Synkope durch timololhaltige Augentropfen. Herz 38:5, pages 556-557.
Crossref
Crossref
Hsien Chan, Catherine McKay, Susan Adams & Orli Wargon. (2013) RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds. Pediatrics 131:6, pages e1739-e1747.
Crossref
Crossref
Matthias Huber, Marita Kölzsch, Ralf Stahlmann, Werner Hofmann, Juliane Bolbrinker, Dagmar Dräger & Reinhold Kreutz. (2012) Ophthalmic Drugs as Part of Polypharmacy in Nursing Home Residents with Glaucoma. Drugs & Aging 30:1, pages 31-38.
Crossref
Crossref
R. Weber, A. Trautmann, W. Randerath, W. Heppt & W. Hosemann. (2012) ASS-ToleranzinduktionAspirin desensitization. HNO 60:4, pages 369-383.
Crossref
Crossref
Serdar Dogan, Mustafa Unal, Nihal Ozturk, Piraye Yargicoglu, Aysegul Cort, Ivan Spasojevic, Ines Batinic-Haberle & Mutay Aslan. (2011) Manganese porphyrin reduces retinal injury induced by ocular hypertension in rats. Experimental Eye Research 93:4, pages 387-396.
Crossref
Crossref
Alan Lukazewski & Janet Kohli. (2011) Minimizing the Risk of Falling. The Consultant Pharmacist 26:7, pages 449-450.
Crossref
Crossref
Joel W. Proksch, Ezra R. Lowe & Keith W. Ward. (2011) Ocular Pharmacokinetics of Mapracorat, a Novel, Selective Glucocorticoid Receptor Agonist, in Rabbits and Monkeys. Drug Metabolism and Disposition 39:7, pages 1181-1187.
Crossref
Crossref
Gerald Liew & Jie Jin Wang. (2011) Manifestaciones vasculares retinianas: ¿reflejan el estado del corazón?. Revista Española de Cardiología 64:6, pages 515-521.
Crossref
Crossref
Gerald Liew & Jie Jin Wang. (2011) Retinal Vascular Signs: A Window to the Heart?. Revista Española de Cardiología (English Edition) 64:6, pages 515-521.
Crossref
Crossref
Marjo Volotinen, Jukka Hakkola, Olavi Pelkonen, Heikki Vapaatalo & Jukka Mäenpää. (2011) Metabolism of Ophthalmic Timolol: New Aspects of an Old Drug. Basic & Clinical Pharmacology & Toxicology 108:5, pages 297-303.
Crossref
Crossref
Berrin Gunaydin & Oya Yalcin Cok. (2011) Hazards of topical ophthalmic drug administration. Trends in Anaesthesia and Critical Care 1:1, pages 31-34.
Crossref
Crossref
Hongzhi YuanMinbin YuYangfan YangKaili WuXianchai LinJinrong Li. (2010) Association of CYP2D6 Single-Nucleotide Polymorphism with Response to Ophthalmic Timolol in Primary Open-Angle Glaucoma—A Pilot Study. Journal of Ocular Pharmacology and Therapeutics 26:5, pages 497-501.
Crossref
Crossref
Aysegul Cort, Nihal Ozturk, Deniz Akpinar, Mustafa Unal, Gultekin Yucel, Akif Ciftcioglu, Piraye Yargicoglu & Mutay Aslan. (2010) Suppressive effect of astaxanthin on retinal injury induced by elevated intraocular pressure. Regulatory Toxicology and Pharmacology 58:1, pages 121-130.
Crossref
Crossref
KK Lau, HW Ng & ML Tse. (2010) Timolol Eye Drops Induced Bradycardia. Hong Kong Journal of Emergency Medicine 17:1, pages 71-74.
Crossref
Crossref
Paul N. Schacknow & John R. Samples. 2010. The Glaucoma Book. The Glaucoma Book
583
628
.
Shu-Feng Zhou. (2009) Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clinical Pharmacokinetics 48:11, pages 689-723.
Crossref
Crossref
Satish R. RajC. Michael SteinPablo J. SaavedraDan M. Roden. (2009) Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120:12, pages 1123-1132.
Crossref
Crossref
Yangfan YangKaili WuHongzhi YuanMinbin Yu. (2009) Cytochrome Oxidase 2D6 Gene Polymorphism in Primary Open-Angle Glaucoma With Various Effects to Ophthalmic Timolol. Journal of Ocular Pharmacology and Therapeutics 25:2, pages 163-172.
Crossref
Crossref
Isaac SchweitzerKay MaguireChee H Ng. (2008) A case of melancholic depression induced by β‐blocker antiglaucoma agents. Medical Journal of Australia 189:7, pages 406-407.
Crossref
Crossref